Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

213
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
213

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Phage intervention improves colitis and response to corticosteroids by attenuating virulence of Crohn's disease-associated bacteria.

Science translational medicine·2026
Same author

Comprehensive cross-cohort analysis reveals global gut microbiome signatures of celiac disease.

Communications medicine·2026
Same author

<i>Saccharomyces boulardii</i> CNCM I-745 synergizes with the small intestinal microbiota to boost AhR signaling in celiac disease.

Gut microbes·2026
Same author

Gene-Environment Interactions in Celiac Disease: The Role of the Intestinal Epithelium.

Lifestyle genomics·2026
Same author

Small intestinal microbial fiber metabolism dysfunction in celiac disease.

Nature communications·2026
Same author

Sex-related differences in cardiovascular inflammation and metabolomics in a humanized transgenic mouse model of celiac disease.

Scientific reports·2026

Video Experimental Relacionado

Updated: Jul 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Protección contra las enfermedades inflamatorias intestinales

Heather J Galipeau1, Elena F Verdu1

  • 1Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada.

Science (New York, N.Y.)
|September 14, 2023
PubMed
Resumen

Las células epiteliales intestinales pueden modular los linfocitos, ofreciendo potencial para nuevas estrategias terapéuticas. Esta interacción puede allanar el camino para nuevos tratamientos dirigidos a las respuestas inmunes.

Más Videos Relacionados

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.6K

Videos de Experimentos Relacionados

Last Updated: Jul 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.6K

Área de la Ciencia:

  • Inmunología
  • Gastroenterología
  • Biología celular

Sus antecedentes:

  • Las células epiteliales intestinales (CEI) juegan un papel crucial en el mantenimiento de la homeostasis intestinal.
  • Los IEC interactúan con las células inmunes, incluidos los linfocitos, influyendo en las respuestas inmunes.
  • La desregulación de las interacciones IEC-linfocitos está implicada en varias enfermedades gastrointestinales.

Objetivo del estudio:

  • Investigar las funciones inmunomoduladoras de las células epiteliales intestinales en los linfocitos.
  • Explorar el potencial de dirigir las interacciones IEC-linfocitos para intervenciones terapéuticas.

Principales métodos:

  • Sistemas de cultivo conjunto de IEC y linfocitos.
  • Análisis de citometría de flujo de las poblaciones de linfocitos.
  • Perfiles de citoquinas para evaluar las respuestas inmunes.

Principales resultados:

  • Las IEC presentan efectos inmunomoduladores significativos en la proliferación y activación de los linfocitos.
  • Se identificaron vías moleculares específicas involucradas en la comunicación IEC- linfocitos.
  • La modulación de las IEC alteró el medio de las citocinas, afectando la diferenciación de las células T.

Conclusiones:

  • Las células epiteliales intestinales poseen potentes capacidades inmunomoduladoras hacia los linfocitos.
  • Dirigirse a las interacciones IEC-linfocitos representa una vía prometedora para desarrollar nuevas terapias para trastornos inmunomediados.